SEC Tracker
Get the app
BBLG · XBRL financial data

Bone Biologics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (BBLG's year ends in late December)

In thousands of dollarsDec 31, 2023†Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Research and development447*2463504301,105*424192188257*142309243
General and administrative713*658459521450*615556527476*663499424
Total operating expenses1,160*9048109511,555*1,038748715733*805808666
Operating income (loss)(1,160)*(904)(810)(951)(1,555)*(1,038)(748)(715)(733)*(805)(808)(666)
Net income (loss)(1,550)*(866)(784)(941)(1,522)*(1,017)(741)(667)(685)*(766)(774)(618)
Earnings per share, basic USD per share—(1.31)0.67(2.37)—(0.32)(1.33)(0.37)—(0.43)(0.43)(0.17)
Earnings per share, diluted USD per share—(1.31)0.67(2.37)—(0.32)(1.33)(0.37)—(0.43)(0.43)(0.17)
Weighted average shares, basic thousands of shares—6611,1681,753—3,1835581,795—1,7951,7973,737
Weighted average shares, diluted thousands of shares—6611,1681,753—3,1835581,795—1,7951,7973,737
  • † Share count changed about 2x in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (BBLG's year ends in late December)

In thousands of dollarsDec 31, 2023†Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents3,0273,2282,3323,5663,3252,7476,6406,0495,3344,5304,0326,088
Total current assets3,7383,8403,1934,0663,8613,1627,0026,3515,7964,9794,4376,432
Total assets3,7383,8403,1934,0663,8613,1627,0026,3515,7964,9794,4376,432
Total current liabilities831165285273378251406334419309512481
Total liabilities831165285273378251406334419309512481
Accumulated deficit(80,909)(81,775)(82,559)(83,500)(85,021)(86,038)(86,779)(87,446)(88,130)(88,896)(89,670)(90,288)
Total stockholders' equity2,9063,6752,9093,7923,4842,9116,5966,0175,3784,6703,9255,952
Total liabilities and equity3,7383,8403,1934,0663,8613,1627,0026,3515,7964,9794,4376,432
Common shares outstanding (cover page) thousands of shares5341,1001,8012,4643,2713,2711,7951,7951,7951,7952,7563,389
  • † Share count changed about 2x in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (BBLG's year ends in late December)

In thousands of dollarsDec 31, 2023†Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)(1,550)*(866)(784)(941)(1,522)*(1,017)(741)(667)(685)*(766)(774)(618)
Stock-based compensation71*5317*18*101*5173*87*46*248*3*
Net cash from operating activities(2,018)*(1,303)(896)*(572)*(1,353)*(926)(459)*(591)*(715)*(804)(518)*(532)*
Proceeds from issuing common stock592*1,504(0)*(0)*0*——0*0*——0*
Net cash from financing activities592*1,5040*1,807*1,112*3484,353*0*0*——2,589*
Net change in cash(1,426)*201(896)*1,234*(241)*(579)3,894*(591)*(715)*(804)(498)*2,056*
  • † Share count changed about 2x in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Bone Biologics6,088not reported(532)*3.4M9.8 quarters 10-QSep 30, 2026
ENvue Medical1,084239(2,691)*11.1M0.4 quarters 10-QJun 30, 2026
SeaStar Medical Holding6,959615(2,994)*4.4M2.3 quarters 10-QJun 30, 2026
Tenon Medical1,6771,279(2,758)*667,0470.6 quarters 10-QJun 30, 2026
Sintx Technologies3,590452(2,767)*6.7M1.3 quarters 10-QJun 30, 2026
OSR Health1,500316(2,421)*35.1M0.6 quarters 10-QJun 30, 2026
Adm Tronics Unlimited223not reported(33)67.6M6.8 quarters 10-QJun 30, 2026
Retractable Technologies2,6417,201(1,732)*29.9M1.5 quarters 10-QJun 30, 2026
Sonoma Pharmaceuticals5,3386,406(649)4.8M8.2 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.